TriAdeno Vaccine + N-803 for Prostate Cancer

This trial tests a new vaccine, TriAdeno, alongside the drug N-803 (an immunotherapy already used for bladder cancer), to determine if they can halt the growth of prostate tumors. It targets individuals with early-stage prostate cancer, where the cancer remains confined to the prostate. Men monitoring their early-stage prostate cancer without needing aggressive treatment might be suitable candidates. Participants will receive both treatments via injections and undergo regular tests and check-ups. As a Phase 2 trial, this research aims to measure the treatment's effectiveness in an initial, smaller group of people.

The trial requires a 6-week break from steroid therapy before starting the study treatment. Other medications are not specifically mentioned, so it's best to discuss your current medications with the trial team.

Previous studies have shown that the combination of the TriAdeno vaccine and N-803 is generally well-tolerated. Research indicates that patients experienced few serious side effects when these treatments were combined. N-803, already approved by the FDA for bladder cancer, has a known safety profile, providing reassurance about its use in prostate cancer trials.

Researchers are excited about the TriAdeno vaccine combined with N-803 for prostate cancer because it offers a new approach to treatment. Unlike standard treatments like hormone therapy, surgery, or chemotherapy, this combination uses a vaccine to stimulate the immune system to target cancer cells. N-803 enhances this immune response, potentially leading to more effective targeting and elimination of cancer cells. This innovative method could offer new hope for patients by potentially providing a treatment that is both more precise and less invasive than traditional options.

Studies suggest that the combination of the TriAdeno vaccine and N-803, which trial participants will receive, may benefit prostate cancer patients. The TriAdeno vaccine helps the body identify and fight cancer by targeting three specific cancer proteins. N-803 boosts important immune cells called T cells and NK (natural killer) cells, which attack cancer cells. Previous research has shown that N-803 can enhance the effectiveness of other cancer treatments. While specific results for prostate cancer are still under investigation, these components have shown promise in treating other types of cancer, indicating they might help prevent prostate tumors from growing.¹²⁴⁶⁷